Pharmacotherapy for Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut. This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective treatments—particularly for the pain component of IBS—although the introduction of drugs directed at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction in IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100 · cited 1×
“Serotonin, or 5-HT, is an important neurotransmitter in the brain and the enteric nervous system, with 90% of the body’s total store of 5-HT contained within the intestinal enterochromaffin cells [50,51].”
BackgroundRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Medically Unexplained Physical Symptoms, Anxiety, and Depression: A Meta-Analytic Review
Henningsen, P., Zimmermann, T., & Sattel, H. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000075977.90337.e7 · Cited by 829
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780 · cited 1×
“Rifaximin, a non-absorbable antibiotic, improved global symptoms and bloating in IBS in several trials, including 2 phase III, randomized, placebo-controlled trials [78,79] comprising more than 1200 patients with non-constipated IBS.”
BackgroundAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614 · cited 1×
“that there was no correlation between improvement in IBS symptoms and depression scores [34–36], and a fourth trial reported that the benefit of desipramine (a TCA) was greater in non-depressed individuals [37].”
ResultFord, A. C., Talley, N. J., Spiegel, B. M. R., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M. M., & Moayyedi, P. (2008) · BMJ · doi:10.1136/bmj.a2313 · Cited by 565
Self-citationChey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., MacDougall, J. E., Jia, X. D., Shao, J. Z., Fitch, D. A., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.254 · Cited by 463 · cited 3×
“Patients with IBS-D have increased postprandial plasma 5-HT, while those with IBS-C have reduced postprandial 5-HT levels [52].”
MethodFord, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.148 · Cited by 405 · cited 1×
“An updated systematic review and meta-analysis [31] identified 17 separate trials of antidepressants with an overall beneficial effect on IBS symptoms: RR of remaining symptomatic 0.”
Self-citationDROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399 · cited 3×
“Patients with IBS-D have increased postprandial plasma 5-HT, while those with IBS-C have reduced postprandial 5-HT levels [52].”
BackgroundTwo randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373 · cited 1×
“The increase in cGMP may also have effects on sensory afferent neurons, leading to pain inhibition, an effect noted in the phase III clinical trials of the drug that were conducted in chronic idiopathic constipation [86], where abdominal discomfort and bloating improved significantly.”
BackgroundWouters, M. M., Balemans, D., Van Wanrooy, S., Dooley, J., Cibert-Goton, V., Alpizar, Y. A., Valdez-Morales, E. E., Nasser, Y., Van Veldhoven, P. P., Vanbrabant, W., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.034 · Cited by 372 · cited 2×
“Histamine sensitizes TRPV1 on neurons from murine dorsal root ganglia and on human submucosal neurons in rectal biopsies via activation of H1 receptors [62].”
BackgroundAtkinson, W., Lockhart, S., Whorwell, P. J., Keevil, B., & Houghton, L. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.09.031 · Cited by 355 · cited 1×
“Patients with IBS-D have increased postprandial plasma 5-HT, while those with IBS-C have reduced postprandial 5-HT levels [52].”
BackgroundEluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334 · cited 2×
“Three large clinical trials, involving a total of over 3000 patients randomized to eluxadoline or placebo, have demonstrated efficacy of eluxadoline in the relief of diarrhea or the composite endpoint of diarrhea and pain over 12 weeks of treatment [48,49].”
BackgroundTRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain
Liu, B., Fan, L., Balakrishna, S., Sui, A., Morris, J. B., & Jordt, S.-E. (2013) · Pain · doi:10.1016/j.pain.2013.06.043 · Cited by 319
The role of mast cells in functional GI disorders
Wouters, M. M., Vicario, M., & Santos, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309151 · Cited by 308 · cited 1×
“Mechanism: Mast cells and their mediators, in particular histamine, serotonin and proteases, are increasingly recognized as contributing to the pathogenesis of IBS [61].”
BackgroundYu, D., Cheeseman, F., & Vanner, S. (2011) · Gut · doi:10.1136/gut.2009.205476 · Cited by 284
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283 · cited 1×
“A meta-analysis of five randomized controlled trials of rifaximin [80], comprising 1803 patients, reported similar efficacy with an NNT of 10 for improvement in global symptoms and bloating.”
MethodMorgan, V (2005) · Gut · doi:10.1136/gut.2004.047423 · Cited by 269 · cited 1×
“The mechanism of action of antidepressants in IBS remains uncertain, reduced activation of pain centers in the anterior cingulate cortex during painful rectal distension in patients with IBS by amitriptyline [30] suggests central effects on pain processing in addition to the effects on peripheral mechanisms that may i…”
BackgroundFord, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261
Self-citationA randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
Ford, A. C., Forman, D., Bailey, A. G., Axon, A. T. R., & Moayyedi, P. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01740.x · Cited by 233
Self-citationAn Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
GORARD, D. A., LIBBY, G. W., & FARTHING, M. J. G. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00273.x · Cited by 211
Houghton, L. A., Fell, C., Whorwell, P. J., Jones, I., Sudworth, D. P., & Gale, J. D. (2007) · Gut · doi:10.1136/gut.2006.110858 · Cited by 204
Quartero, A. O., Meiniche-Schmidt, V., Muris, J., Rubin, G., & de Wit, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub2 · Cited by 190
Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits
Camilleri, M., Lembo, A., & Katzka, D. A. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.05.014 · Cited by 176 · cited 1×
“Opioid receptor agonists slow GI and colonic transit, increase fluid absorption and reduce pain sensation—a review of the overall effects on different regions of the gut appears elsewhere [43].”
BackgroundBrenner, D. M., Fogel, R., Dorn, S. D., Krause, R., Eng, P., Kirshoff, R., Nguyen, A., Crozier, R. A., Magnus, L., & Griffin, P. H. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0026-7 · Cited by 145
Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3157-8 · Cited by 143 · cited 1×
“Some patients with IBS may have underlying small intestinal bacterial overgrowth (SIBO), detected on hydrogen breath testing, and this can be reversed with non-absorbable antibiotics such as rifaximin [76].”
BackgroundMiner, P. B., Koltun, W. D., Wiener, G. J., De La Portilla, M., Prieto, B., Shailubhai, K., Layton, M. B., Barrow, L., Magnus, L., & Griffin, P. H. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.611 · Cited by 141 · cited 1×
“In addition to published efficacy in patients with chronic idiopathic constipation [90], there are preliminary reports of efficacy in patients with IBS-C [91].”
BackgroundFukudo, S., Kinoshita, Y., Okumura, T., Ida, M., Akiho, H., Nakashima, Y., Nishida, A., & Haruma, K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.047 · Cited by 125
Chey, W. D., Lembo, A. J., & Rosenbaum, D. P. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.41 · Cited by 102 · cited 1×
“A phase 2 dose-response study included 356 patients with IBS-C, of whom 305 completed the study [92].”
MethodEffects of menthol on circular smooth muscle of human colon: Analysis of the mechanism of action
Amato, A., Liotta, R., & Mulè, F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.018 · Cited by 98 · cited 1×
“Menthol inhibits smooth muscle contractility in the GI tract by blocking calcium influx, via L-type calcium channels in the plasma membrane of smooth muscle cells [20,21].”
BackgroundAziz, I., Mumtaz, S., Bholah, H., Chowdhury, F. U., Sanders, D. S., & Ford, A. C. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.03.002 · Cited by 87 · cited 1×
“About 25% of patients with IBS-D have evidence of bile acid malabsorption based on 75SeHCAT scanning [72] or biochemical testing of serum or stool [73].”
BackgroundSelf-citationAntidepressant Treatment and Risk of Dementia: A Population-Based, Retrospective Case-Control Study
Lee, C. W.-S., Lin, C.-L., Sung, F.-C., Liang, J.-A., & Kao, C.-H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09580 · Cited by 61
Kaplan, A., Franzen, M. D., Nickell, P. V., Ransom, D., & Lebovitz, P. J. (2014) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.838632 · Cited by 54
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Self-citationDiagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Self-citationMohsenabadi, H., Zanjani, Z., Shabani, M. J., & Arj, A. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.07.003 · Cited by 26
Metadata
- Authors
- Camilleri, M., & Ford, A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2017-10-27
- Volume
- 6
- Issue
- 11
- Pages
- 101
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2765897010
- Cited by
- 46
- References
- 36
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.